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sample was reduced to a still balanced subsample of 70 patients. VAS ratings were 
transformed into utilities by specifying a power function. A multiplicative-form MAUF 
was estimated following the standard methodology. RESULTS: Individual utilities 
from TOOL MAUF showed adequate unbiased predictive validity. Good convergent 
validity was evidenced, since estimated utilities presented strong correlations with 
utilities from generic HRQoL instruments: SF6D (0.664, p  0.001), EQ5D (0.690, p 
 0.001)); and moderate correlations with the rest of instruments included: PANSS 
(0.275, p  0.100), YMRS (0.296, p  0.080), MADRS (0.483, p  0.001), UKU 
(0.424, p  0.002). Criterion validity was also met, as differences in mean utilities 
by clinical severity were found (p  0.008). Interestingly, utilities from TOOL MAUF 
covered a wider range of health states (0.037, 1.000) than those from SF6D and EQ5D 
(0.233, 0.960), since TOOL is a speciﬁc instrument. CONCLUSIONS: Utilities from 
TOOL MAUF show good psychometric properties and cover a wider range of health 
states than utilities from other generic HRQoL instruments.
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OBJECTIVES: The purpose of this study was to describe the current situation of Post 
Traumatic Stress Disorder (PTSD) among Hungarian prehospital ambulance staff and 
make suggestions for the workplace. METHODS: In the study we involved 60 persons 
at ﬁve ambulance station in Pest county randomly. Standardized self-ﬁll-in PTSD and 
burn out questionnaire were used in an interview process to collect information. The 
items included PTSD symptoms, coping mechanisms, social support and burn out. 
Data collection was carried out in 2008 and statistical analysis as one-way analysis 
of variance (ANOVA) was performed with SPSS 14.0. RESULTS: All respondents 
were male with an average age 33,2 years. More than two third (66.7%) of all people 
spent 1–5 years with ambulance service. Eightoeen out of 60 suffer on a chronic condi-
tion, mainly in locomotion system. The PTSD symptoms are present in 17 (28.3%) 
ambulance man and they can get support from colleagues (75%), family (66.7%) and 
friends (58.35) and very rearly from professionals, like psychologist (6.7%). The 
respondents indicated “No one would help” in 8,3%. Regarding to burn out: 15% is 
in danger, in 5% in burnt out. The half of the respondents are at risk of symptoms 
of burn out. The symptoms of PTSD and burn out correlated with no active sport 
(p  0.05), with a second job (p  0.05) and poor working conditions (p  0.05). 
CONCLUSIONS: The results showed a high percentage of PTSD symptoms and 
risk of burn out which needs already treatment. Health promotion at work place, 
coaching techniques and a pschychologist at work place can provide a better outcome 
for ambulance personnel.
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OBJECTIVES: To evaluate in a cohort of depressed patients if response within the 
ﬁrst 6 weeks of antidepressant treatment (AD) is associated with a change in health-
related quality of life (HRQoL) after 1-year follow-up. METHODS: This is a 1-year, 
longitudinal, prospective and multicenter study of a cohort of outpatients with major 
depression. Main objective was to assess the predictive value of early antidepressant 
response in long-term good outcome. Patients were included when they started an AD 
for index episode. Early response was deﬁned as a 50% improvement on the 17-Item 
Hamilton Depression Rating Scale total score (HAM-D17) within the ﬁrst 6 weeks, 
and good outcome when the patient achieved remission (HAM-D17 a7) in the ﬁrst 6 
months and remained in remission until end of follow-up. HRQoL was scored by the 
European Quality of Life-5 Dimensions (EQ-5D). The change of the scoring from 
baseline to end of follow-up in the EuroQol was analyzed by means of an ANCOVA 
model. RESULTS: 930 patients were included in the study. At baseline, mean age was 
47.1 years (SD, 13.5), 67.9% were female and mean HAM-D17 score was 24.2 (SD, 
5.5). 355 patients (38.2%) showed early response and of those 76.1% had a good 
outcome, versus 43% of those patients without early response. The baseline EQ-5D 
index raw scores (95% Conﬁdence interval, CI) improved from 0.25 (0.22–0.29) to 
0.91 (0.89–0.93) among patients who showed early response, and from 0.23 (0.21–
0.26) to 0.81 (0.79–0.83) among those without it. Improvement in EQ-5D scores was 
associated with early response, gender, having lower baseline HRQoL (EQ-5D), higher 
depressive scores (HAM-D17) and higher level of anxiety (HAM-A). Moreover there 
were interactions found between gender and early response. CONCLUSIONS: 
Depressed patients experienced improvements in HRQoL after starting AD. This 
improvement was associated with early antidepressant response.
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OBJECTIVES: Olanzapine Long-Acting Injection (OLAI) was developed to provide 
individuals with schizophrenia, particularly those who struggle with adherence, with 
an effective and convenient alternative to oral antipsychotics. The present study com-
pared quality of life and patient-reported outcomes between oral and long-acting 
injectable formulations of olanzapine in the treatment of schizophrenia. METHODS: 
Clinician-rated quality of life and patient-reported outcomes were evaluated in a 24-
week double-blind, randomized clinical trial comparing OLAI with oral olanzapine in 
clinically stabilized individuals with schizophrenia. The measures used included the 
Heinrichs-Carpenter Quality of Life Scale (QLS), the Short Form Health Survey (SF-
36), and the Drug Attitude Inventory (DAI). RESULTS: Of the 1065 randomized 
individuals, the majority were male (65.4%) and Caucasian (71.8%), with a mean 
age of 39 years and a baseline PANSS Total score of 55.9 (SD  15.6). In general 
changes in QLS, SF-36, and DAI for individuals on OLAI were similar to those for 
individuals receiving oral olanzapine with the exception of statistically signiﬁcant dif-
ferences on some SF-36 subscales. However these differences across treatment groups 
were not considered clinically meaningful. Despite examination in a symptomatically 
stable population, signiﬁcant improvements in quality of life as measured by the QLS 
total scores were seen in the group taking OLAI for two of the three therapeutic doses 
(405 mg/4 wk, p  0.001 and 300 mg/2 wk, p  0.003) and the group taking oral 
olanzapine (p  0.001). There were no signiﬁcant differences in QLS across treatment 
groups. CONCLUSIONS: Subjects remained stable over the course of the study, and 
many experienced an increase in quality of life regardless of assignment to OLAI or 
oral olanzapine. The ﬁndings suggest symptomatically stable individuals receiving 
OLAI will maintain health outcomes comparable with those taking oral olanzapine. 
OLAI may be useful for individuals who desire the effectiveness of olanzapine without 
requiring daily dosing.
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OBJECTIVES: To investigate the health status and quality of life of demented patients 
in Hungary, examining the correlation between disease characteristics and quality of 
life (QoL). Also to compare QoL results of the demented patients with the general 
Hungarian population’s scores by age-groups. METHODS: A cross-sectional study of 
88 consecutive patients was conducted in 2008 involving 3 GP and 1 outpatient set-
tings. Investigating the health related quality of life, EuroQoL (EQ-5D) questionnaire 
was applied and completed by assistants’ guidance. Mini-Mental State Examination 
(MMSE) and Resource Utilization in Dementia (RUD) questionnaire were completed 
as well. Negatives EQ-5D scores were replaced by 0. Spearman correlation coefﬁcients 
were performed. RESULTS: Eighty-eight patients (59% female) were involved in the 
survey with mean age of 78 years (SD 8.5) and average disease duration of 4.3 years 
(SD 5.1). Mean MMSE was 16.7 (SD 7.24) and EQ-5D score was 0.401 (SD 0.327). 
Average EQ-5D values of the general Hungarian population aged 65–74, 75–85 and 
85 years were 0.756, 0.634 and 0.629, respectively, whilst these values were 0.530, 
0.424 and 0.220 in our sample. Signiﬁcant correlation was observed between EQ-5D 
score and disease duration, MMSE score, and the time-resource utilization (physical 
and instrumental activities of daily living as well as supervision hours), at p  0.01. 
For mild (MMSE 18–23), moderate (MMSE 10–17) and severe (MMSE 0–9) dementia 
the EQ-5D values decreased by disease severity, with mean values of 0.56 (SD. 0.28), 
0.29 (SD. 0.32) and 0.19 (SD. 0.31), respectively. Although for mild cognitive impair-
ment (MMSE 24–30) it resulted in lower values than in mild dementia, with mean 
0.53 (SD. 0.33) CONCLUSIONS: Dementia causes a signiﬁcant decline in the quality 
of life, diminishing EQ-5D values by disease severity. EQ-5D values are remarkably 
lower in all age groups among demented people compared to general population.
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OBJECTIVES: While the effects of dementia on patients are well documented, aware-
ness of its negative impact on the life of caregivers needs to be increased. The objective 
of this survey was to provide data from physicians and caregivers on the impact of 
dementia on both patients and carers. METHODS: Adelphi’s Dementia Disease Spe-
ciﬁc Programme is an independent real world observational survey of cognitively 
impaired patients aged over 50 managed by primary or secondary care physicians in 
ﬁve European countries during 2008. Information from non-professional caregivers 
was collected using a prospective questionnaire including details of employment status, 
patient accommodation, patient’s current symptoms, patient compliance with treat-
ment and the carer’s quality of life measured by a validated instrument (Zarit Care-
giver Burden Interview). RESULTS: The caregiver questionnaires (n  847) showed 
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that approximately one in ten had had to change their employment status in order to 
look after the patient, usually a reduction in the number of hours worked. Half of the 
caregivers who had reduced their work hours reported a subsequent loss in income 
(ranging from a575 per month in France to a170 in the UK). 113 caregivers (13%) 
indicated that they receive medication to treat a condition brought on or exacerbated 
by their caregiver role, most frequently anxiety, depression and/or insomnia. Care-
givers also reported signiﬁcant impact on their social lives with 51% recording 
reduction in time available for themselves, 48% indicating a decrease in social activi-
ties and a quarter mentioning reduced ﬁtness. CONCLUSIONS: Caregiving is asso-
ciated with reduced employment and a negative ﬁnancial impact. It may result in 
less free time, social activity, poorer health due to reduced ﬁtness and increased 
medication. The emotional burden of seeing a loved-one suffer is high; however, the 
ﬁnancial and physical health implications of being a caregiver should not be 
underestimated.
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OBJECTIVES: Health plans calculate daily average consumption (DACON) to 
compare utilization and costs-per-day of therapy across medications with similar 
therapeutic indications. The purpose of this study is to examine DACON for dulox-
etine across its US-approved indications in major depressive disorder (MDD), general-
ized anxiety disorder (GAD), diabetic peripheral neuropathic pain (DPNP), and 
ﬁbromyalgia (FM) and to compare these results with those for venlafaxine-XR and 
pregabalin. METHODS: A retrospective analysis of commercially insured patients 
from large US health plans receiving q1 prescription for duloxetine, venlafaxine-XR, 
or pregabalin during 2006 and 2007 was conducted. MDD and GAD patient sub-
groups were constructed for duloxetine and venlafaxine-XR and DPNP and FM for 
duloxetine and pregabalin. Subgroup assignments were based on ICD-9 diagnosis 
codes recorded during the 12 months prior to the ﬁrst prescription for each index 
medication during the study interval. DACON was calculated by dividing total units 
dispensed by total days of supply. Units-per-day were converted to costs-per-day using 
June 2009 new wholesale prices.1 RESULTS: A total of 79,119 duloxetine, 97,369 
venlafaxine-XR, and 50,512 pregabalin patients were included in the 2007 analysis. 
DACON for duloxetine was 1.31 capsules per day, ranging between 1.27 for DPNP, 
1.33 for GAD, 1.39 for FM, and 1.52 for MDD. Average daily cost for duloxetine 
was $5.20 varying from $5.07 (DPNP) to $6.06 (MDD). DACONs for venlafaxine-
XR and pregabalin were 1.61 and 2.49, respectively. Duloxetine and pregabalin had 
similar average daily costs among patients with DPNP or FM, while the numbers were 
signiﬁcantly lower for duloxetine than venlafaxine-XR among patients with MDD or 
GAD. Results for 2006 were similar. CONCLUSIONS: Duloxetine has stable DACON 
across disease states and over time. Average daily costs were similar for duloxetine 
and pregabalin, but better for duloxetine versus venlafaxine-XR. 1First DataBank’s 
National Drug Data File™ accessed via Analysource Online, June, 2009.
PMH71
SOCIODEMOGRAPHIC FACTORS AND TOXIC HABITS RELATED TO 
STUDENT DRUG USE: THE CASE OF THE TECHNOLOGICAL 
EDUCATIONAL INSTITUTE OF ATHENS
Carayanni V, Papageorgiou E, Demsia S, Roussou K, Zaﬁri M
TECHNOLOGICAL EDUCATIONAL INSTITUTE OF ATHENS, EGALEO, ATTIKI, Greece
OBJECTIVES: The academic area of the Tertiary Education constitutes an important 
ﬁeld of adjustment and transaction of the young in the post adolescence age with 
particular tensions, pressures and stress. The objectives of this study are to focus on 
the extent of drug use in this student community and the investigation of the relation-
ship between socioeconomic factors, toxic habits and drug use. METHODS: The 
sampling was selected out of a population of 27,930 students according to stratiﬁed 
sampling weighed by gender, department and semester. The sample size was 829 stu-
dents, that is sufﬁcient for the estimation of the proportion of users with a signiﬁcance 
level of 0.05. The questionnaire comprised 83 items concerning sociodemographic and 
economic characteristics, adjustment to the academic environment and use of sub-
stances. RESULTS: A total of 161 persons, (19.4%) have used drugs at least once. 
There are signiﬁcant differences (p  0.01) between users and non users concerning: 
gender, relations between parents, satisfaction on study, alcohol use, smoking, number 
of cigarettes/day, friends that are drug users, age of smoke beginners, spending the 
night. Discriminant analysis has indicated that the discriminant factors between depen-
dents/on a crucial phase, before dependence and non users are: friends that are drug 
users (0.707), alcohol use (0.627), age of smoke beginners (0.608), relationship 
between parents (0.392). CONCLUSIONS: It is evident the resulting relationship 
between illegal and legal psychotropic substances. Consequently, prevention policy 
should not ignore tobacco and alcohol use. Additionally it is evident the predominant 
role of the social environment in the use of substances.
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OBJECTIVES: Benzodiazepines (BZDs) as anxiolytics, sedatives and hypnotics are 
frequently prescribed in daily medical practice worldwide and their abuse also becomes 
a target of public health measures. Because frequent attenders to emergence depart-
ments (EDs) sometimes display different psychological features, the utilization pattern 
of BZDs among this group of patients deserves investigations. METHODS: The data 
sources came from the historical claims datasets of 1,000,000-person cohort 
(LHID2005) in 2007, offered by the National Health Insurance Research Database in 
Taiwan. BZDs were deﬁned as those drug items belonging to groups of N03AE, 
N05BA, N05CD and N05CF in the ATC (Anatomical Therapeutic Chemical) classi-
ﬁcation system. For each beneﬁciary, the annual numbers of visits to EDs of hospitals 
and ambulatory visits to practicing clinics and outpatient departments of hospitals 
(excluding visits to dentistry and traditional Chinese medicine) with BZDs prescrip-
tions in 2007 were calculated. RESULTS: Among the valid 962,768 beneﬁciaries of 
the 1,000,000-person cohort, 157,865 (16.4%) patients (96,004 females and 61,861 
males; mean age 52.0 o 17.8 [SD] years) had received BZDs during ambulatory visits 
and 156,259 (16.2%) patients (76,644 females and 79,615 males; mean age 38.5 o 
23.5 [SD] years) had visited EDs in 2007. Among the 806,509 beneﬁciaries who did 
not visit EDs in 2007, only 14.5% (n  116,554) had ever received BZDs at ambula-
tory visits during the year. In contrast, 26.4% (n  41,311) of the ED attenders had 
received BZDs: the percentage rose from 22.6% in one-time ED attenders to 78.8% 
in those having more than 12 ED visits in a year. CONCLUSIONS: The use of BZDs 
was strongly associated with ED visits in Taiwan. Further stratiﬁed analyses are 
required to elucidate this phenomenon.
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OBJECTIVES: Medicine abuse is deﬁned as the recurrent use of a medicine in a non-
medical manner for non-medicinal purposes. The potential for abuse of combination 
(polycomponent) analgesics is high. The primary aim was to detect the potential abuse 
of combination analgesics using a medicine claims database. METHODS: An analysis 
of the South African combination analgesic market was made. Thereafter, a retrospec-
tive, exposure-cohort drug utilisation study was conducted on a medicine claims 
database of a medical aid administrator. The medicine ﬁle contained 1,357,717 
records for 2007. RESULTS: From the analysis of the combination analgesics avail-
able, it was found that there were 21 Schedule 5 (prescription-only) tablet formula-
tions (trade names) containing the following identical active ingredients: 320 mg 
paracetamol, 8 mg codeine phosphate, 32 mg caffeine and 50 mg meprobamate. From 
the database study, a total of 145,372 analgesics were prescribed (36.82% were avail-
able without a prescription). Combination analgesics accounted for 30.21% of all 
analgesics prescribed (92,181 products at a cost of R2,784,484). Analgesics were often 
prescribed on an acute basis in excessive quantities, for example 200 tablets. Combina-
tion analgesic tablets and capsules were also often dispensed to children in large 
quantities. For example, 10 prescriptions for 100 tablets of an over-the-counter com-
bination analgesic and eight prescriptions for 100 capsules of a prescription-only 
combination analgesic, were dispensed to children under seven years, while a syrup 
(a more suitable dosage form) was available. There was furthermore concern about 
the quantities of analgesics prescribed to speciﬁc families and it was clear that if the 
medical aid beneﬁt of one family member was exhausted, the analgesic was claimed 
under another family member’s name. A number of prescribers were identiﬁed who 
were over-prescribing speciﬁc analgesics. CONCLUSIONS: A medical aid database 
can be used to detect analgesic abuse and guidelines to control abuse and cost were 
proposed.
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OBJECTIVES: Although health spending is well below the OECD average when con-
sidered as a share of GDP, Slovakias pharmaceutical expenditures accounts 32% of 
total health care budget. The accessibility and availability of innovative drugs is good. 
Mandatory HTA (pharmacoeconomy) is incorporated in all relevant legislation, MoH 
set the ofﬁcial threshold by l1  a18,000/QALY and l2  a26,500/QALY. METHODS: 
We have analysed the legislation and ofﬁcial reimbursement decisions and commentar-
ies, published by the MoH in 2009. We analysed the applicants documentation 
including pharmacoeconomic analysis, as a mandatory part of the application. 
RESULTS: The main drug reimbursement body—Categorisation committee of the 
MoH—and pharmacoeconomic advisory committee evaluated the applicants dossier 
for the drug agomelatine (Valdoxan®, Servier Slovakia) for the treatment of depres-
sion. The pharmacoeconomic part of the application fulﬁled all legislative aspects. The 
CUA analysis was taken from Swedish pharmacoeconomic model and extrapolated in 
Slovak environment. CMA in Slovak conditions shows lower drug costs for agomela-
